Somewhat Favorable Media Coverage Somewhat Unlikely to Impact REGENXBIO (NASDAQ:RGNX) Share Price
News coverage about REGENXBIO (NASDAQ:RGNX) has trended somewhat positive on Monday, Accern reports. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. REGENXBIO earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.2062187161828 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- REGENXBIO Inc. (NASDAQ:RGNX) Expected to Announce Earnings of -$0.81 Per Share (americanbankingnews.com)
- Investor Watch: Numbers in Review For Avanco Resources Ltd (trikkles.com)
- REGENXBIO Inc. (RGNX) Set to Announce Quarterly Earnings on Tuesday (americanbankingnews.com)
- REGENXBIO to Host Conference Call on August 8 to Discuss Second Quarter 2017 Financial Results and Recent Operational Highlights (finance.yahoo.com)
- REGENXBIO, Inc. – Value Analysis (NASDAQ:RGNX) : August 1, 2017 (finance.yahoo.com)
Shares of REGENXBIO (RGNX) traded up 0.27% on Monday, hitting $18.60. The stock had a trading volume of 102,740 shares. REGENXBIO has a 52 week low of $8.44 and a 52 week high of $24.55. The stock’s 50-day moving average price is $19.72 and its 200 day moving average price is $19.36. The company’s market cap is $573.27 million.
REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.06. The business had revenue of $0.46 million for the quarter. REGENXBIO had a negative return on equity of 39.52% and a negative net margin of 1,595.18%. On average, analysts predict that REGENXBIO will post ($3.12) EPS for the current year.
A number of research analysts have recently commented on RGNX shares. Zacks Investment Research upgraded REGENXBIO from a “sell” rating to a “hold” rating in a report on Saturday, April 15th. Chardan Capital upped their price target on REGENXBIO from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, April 11th.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact REGENXBIO (NASDAQ:RGNX) Share Price” was first posted by Daily Political and is owned by of Daily Political. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.dailypolitical.com/2017/08/07/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-regenxbio-nasdaqrgnx-share-price.html.
In related news, CFO Vittal Vasista sold 3,100 shares of the business’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $18.75, for a total value of $58,125.00. Following the completion of the sale, the chief financial officer now directly owns 107,512 shares in the company, valued at approximately $2,015,850. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kenneth T. Mills sold 6,500 shares of the business’s stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $19.68, for a total value of $127,920.00. Following the completion of the sale, the insider now owns 119,396 shares of the company’s stock, valued at $2,349,713.28. The disclosure for this sale can be found here. Insiders sold a total of 19,200 shares of company stock valued at $368,746 over the last 90 days. 17.00% of the stock is currently owned by corporate insiders.
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.